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Introduction: The Mini-Mental State Examination (MMSE) is a common cognitive screening test, but its utility in
identifying impairments in survivors of acute respiratory failure is unclear. The purpose of this study was to evaluate
MMSE performance versus a concurrently administered detailed neuropsychological test battery in survivors of
acute respiratory failure.
Methods: This cross-sectional analysis used data from the ARDSNet Long Term Outcomes Study (ALTOS) and
Awakening and Breathing Controlled Trial (ABC). Participants were 242 survivors of acute respiratory failure. The
MMSE and detailed neuropsychological tests were administered at 6 and 12 months post-hospital discharge for the
ALTOS study, and at hospital discharge, 3 and 12 months for the ABC study. Overall cognitive impairment identified
by the MMSE (score <24) was compared to impairments identified by the neuropsychological tests. We also
matched orientation, registration, attention, memory and language domains on the MMSE to the corresponding
neuropsychological test. Pairwise correlations, sensitivity, specificity, positive and negative predictive values, and
agreement were assessed.
Results: Agreement between MMSE and neuropsychological tests for overall cognitive impairment was fair (42 to
80%). Specificity was excellent (≥93%), but sensitivity was poor (19 to 37%). Correlations between MMSE domains
and corresponding neuropsychological tests were weak to moderate (6 months: r = 0.11 to 0.28; 12 months: r = 0.09
to 0.34). The highest correlation between the MMSE and neuropsychological domains was for attention at 6 months
(r = 0.28) and language at 12 months (r = 0.34).
Conclusions: In acute respiratory failure survivors, the MMSE has poor sensitivity in detecting cognitive impairment
compared with concurrently administered detailed neuropsychological tests. MMSE results in this population should be
interpreted with caution.Introduction
Many survivors of acute respiratory failure experience
long-term cognitive impairments across a variety of cogni-
tive domains, including attention, memory, mental pro-
cessing speed and executive function [1-6]. To evaluate
such impairments, comprehensive neuropsychological test* Correspondence: mona.hopkins@imail.org
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creativecommons.org/publicdomain/zero/1.0/batteries are commonly used [7-11]. However, such batter-
ies require trained personnel, expensive licensing fees and
several hours per patient for test administration and scor-
ing. Hence, valid cognitive screening tests that are inex-
pensive, brief and easy to administer would be invaluable
in identifying which survivors may develop long-term cog-
nitive impairment [2]. Furthermore, cognitive screening
tests may aid in understanding risk factors and trajectories
of cognitive impairments [5,12], and may facilitate the de-
velopment and evaluation of targeted interventions to ad-
dress cognitive impairments [13,14].le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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commonly used screening test for cognitive impairment
in both clinical practice [15,16], and research [17-24].
Among older adults, the MMSE is the most widely used
cognitive screening test, with a pooled sensitivity of 88%
and specificity of 86% [15]. Moreover, the MMSE has
good performance in identifying mild cognitive impair-
ment in older adults [14], identifying subtypes of mild
cognitive impairment [25] and predicting cognitive im-
pairment in patients with post-operative delirium [26].
As a result of these favorable performance characteris-
tics, the MMSE has been commonly used to assess cog-
nitive outcomes in critical care populations [17-22,24].
However, the performance of the MMSE has not been
specifically evaluated in acute respiratory failure survi-
vors. Understanding whether the MMSE can accurately
screen for cognitive impairment in this patient popula-
tion would provide important new insights. Hence, the
objective of this study is to assess whether the MMSE
can detect cognitive impairment, as assessed by a con-
currently administered, detailed neuropsychological test
battery, in survivors of acute respiratory failure. Addition-
ally, this study explored whether the timing of patient
follow-up assessment after hospital discharge or patient
characteristics influenced the relationship between the
MMSE and the neuropsychological test battery.
Methods
Participants
We conducted a cross-sectional secondary analysis of
data from two prospective studies of acute respiratory
failure patients requiring mechanical ventilation in an
ICU. The data from the first study came from the Na-
tional Institutes of Health-funded ARDS Network Long
Term Outcomes Study (ALTOS), which evaluated 6 and
12 month outcomes from patients enrolled in multi-site
randomized trials conducted by the ARDS Network
from July 2008 to May 2012 [19,27-30]. The patients
from these trials had similar eligibility criteria and were
enrolled from the same study sites during a similar time
frame; as such the data were pooled for this study. Pa-
tients in the ALTOS study who completed the MMSE
and a concurrent neuropsychological test battery at
either 6- or 12-month follow-up (N = 200) were included
in the current study.
To increase the generalizability of this evaluation, data
from a second study were evaluated. The Awaken and
Breathing Controlled (ABC) study evaluated long-term
neurocognitive outcomes in patients enrolled at a single
hospital in Nashville, Tennessee, between October 2003
and March 2006 [31]. Patients from a sub-study of the
ABC study patients were included here [31]. The follow-
ing baseline and ICU data were obtained: age, gender,
race, years of education, employment status, Charlsoncomorbidity index [32] and psychiatric comorbidity (as
described further below), severity of illness, mechanical
ventilation duration, and ICU and hospital length of stay.
ALTOS Study
In the ALTOS study, patients were administered the
MMSE and a standardized neuropsychological test bat-
tery at 6- and 12-month follow-up [27]. The MMSE was
administered via telephone using a validated 26-item
version [33], while the neuropsychological battery was
administered in person by research assistants who under-
went detailed training and quality assurance evaluations
by RH. The telephone version of the MMSE differs from
the in-person MMSE in that it excludes the following
items: 1) A question about orientation to place, which asks
‘What floor of the building are we on?’; 2) A question re-
lated to following commands which asks the patient to
‘close your eyes’; 3) A question related to simple sentence
construction that asks the patient to ‘write a sentence’ 4)
A question related to visuospatial construction that asks
the patient to ‘copy overlapping pentagons’. Additionally,
the telephone version uses only one naming item, as op-
posed to three items in the standard MMSE [33]. The
MMSE telephone score was converted to the standard
30-point scale of the standard MMSE using previously
published methods [33]. The MMSE assesses overall cog-
nitive impairment based on five cognitive domains: 1)
orientation (orientation to time and place), 2) registration
(registration of three words), 3) attention (backward
spelling of ‘WORLD’), 4) memory (recall of three words)
and 5) language (naming, repetition and following a
three-stage command) [34].
Similar cognitive domains were identified from the
neuropsychological test battery, which is made up of
widely used neuropsychological tests with known reli-
ability and validity [35-37]. The domains included: 1)
orientation from the Neurobehavioral Cognitive Status
Examination orientation total score [38]; 2) registration
from the Digit Span’s raw forward score from the
Wechsler Adult Intelligence Scale-Third Edition [39,40];
3) attention from the Digit Span’s total age-adjusted
score and the raw forward and backward scores from
the Wechsler Adult Intelligence Scale-Third Edition
[39,40]; 4) memory from the Logical Memory I and Lo-
gical Memory II age-adjusted scores from the Wechsler
Memory Scale-Third Edition [39,40] and 5) language via
the Verbal Fluency test [41]. MMSE scores for each
domain were compared to scores for the corresponding
neuropsychological test (recognizing there is not neces-
sarily a one-to-one correspondence between the tests in
the domains of interest between the MMSE and neuro-
psychological test battery). We also compared overall
cognitive impairment between the MMSE and the neuro-
psychological test battery.
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sent if the patient had any of the following (based on med-
ical chart review): current or past excessive alcohol use,
illicit drug use or drug rehabilitation, diagnosis or treat-
ment for psychiatric disorder or documented history of
depression or anxiety [19,42]. Depression and anxiety
were assessed at 6 and 12 months using the Hospital Anx-
iety and Depression Scale, which provides separate sub-
scale scores for depression and anxiety. Scores of eight or
higher indicate probable depression or anxiety [19,43].
ABC study
In the ABC study, patients were administered the MMSE
and a detailed neuropsychological test battery in person at
hospital discharge, and at 3- and 12-month follow-up, by
a single neuropsychologist [31]. To examine generaliz-
ability of the primary ALTOS study analyses, we evalu-
ated the ability of the MMSE to detect overall cognitive
impairment compared to a similar neuropsychological
test battery in the ABC study [31]. The ABC study test
battery included: 1) Digit Span and Digit Symbol from
the Wechsler Adult Intelligence Scale-Third Edition [39,40];
2) the Rey Auditory Verbal Learning Test (RAVLT) [44];
3) Rey-Osterreith Complex Figure-Copy and Delayed Re-
call [45]; 3) Trail Making Test Parts A and B [46] and 4)
Verbal Fluency test [47]. We also used data from the ABC
study to compare the MMSE attention domain with the
Digit Span scores [39].
Statistical analysis
Cross-sectional data analysis compared MMSE scores
with neuropsychological test scores at 3, 6 and 12 months.
Cognitive impairment was defined for the MMSE as total
scores <27 and <24, which represent widely used, highly
sensitive and specific cutoff scores for cognitive impair-
ment [17,48]. Sensitivity and specificity were similar when
comparing total MMSE scores of <27 and <24 versus
neuropsychological test scores; therefore, we only report
the more conservative cutoff of <24. For the neuropsycho-
logical test batteries, cognitive impairment was conserva-
tively defined, as done in prior studies [19,27,31], as
having at least one cognitive test ≥2 standard deviations
below population norms (bottom 2.5%), or at least two
tests ≥1.5 standard deviations below population norms
(bottom 6.7% for both tests). The ability of the MMSE to
detect cognitive impairment was evaluated using sensitiv-
ity, specificity, positive and negative predictive values, and
agreement. The area under the receiver operating charac-
teristics curves was also used to examine the ability of the
total MMSE score to discriminate between survivors with
and without cognitive impairment, as defined by the
neuropsychological test battery [19,27-31].
Pearson correlations were used to examine the relation-
ship between MMSE cognitive domains and thecorresponding cognitive domains from the neuropsycho-
logical test results. We examined whether these relation-
ships were affected by patient characteristics. Correlations
were calculated within relevant patient subgroups defined
by age (dichotomized at the mean age of 50 years), gender,
education level (dichotomized at the mean of 12 years,
that is, high school graduation), depression and anxiety
status at 6 and 12 months using the Hospital Anxiety and
Depression Scale [43], and pre-existing psychiatric comor-
bidity prior to acute respiratory failure. Statistical signifi-
cance was defined as P ≤0.05 and statistical analyses were
completed using STATA 12.0 (StataCorp, College Station,
TX, USA). This study was conducted in accordance with
the amended Declaration of Helsinki. All studies obtained
informed consent from participants, and were approved
by relevant institutional review boards (ALTOS: Johns
Hopkins School of Medicine Institutional Review Board-5
approval number: NA_00013113; ABC: Vanderbilt Uni-
versity and Saint Thomas Hospital Institutional Review
Board number: 030803).
Results
In the ALTOS study, of the 200 eligible patients, 181
and 174 patients completed both the MMSE and the
neuropsychological tests at 6 and 12 months, respect-
ively. In the ABC study, 61, 69 and 47 participants com-
pleted both the MMSE and neuropsychological tests at
hospital discharge, 3 months and 12 months, respect-
ively. Respondents in both studies were predominately
white, middle-aged and male, with a mean of approxi-
mately 12 years of education (Table 1). Pre-ICU psychi-
atric comorbidity was common, with a prevalence of
42% in the ALTOS study and 74% in the ABC study. All
patients were mechanically ventilated, and the mean
ICU length of stay was 14 and 10 days in the ALTOS
and ABC studies, respectively. For the ALTOS study,
12% and 10% of patients had MMSE scores <24 at 6 and
12 months, respectively; while 38% and 25% of patients
had cognitive impairments based on the neuropsycho-
logical test scores at 6 and 12 months. In the ABC study,
the percentage of patients with an MMSE score <24 was
33%, 17% and 13% at discharge, 3 months and 12 months
respectively; while 90%, 79% and 71% had cognitive im-
pairments based on the neuropsychological test scores at
these same time points, respectively.
Comparing overall cognitive impairment
For the ALTOS study, at 6 and 12 months, overall agree-
ment was 67% and 80%, respectively. Kappa indicated
poor concordance after accounting for chance agree-
ment (0.19 and 0.34). At 6 and 12 months, the specificity
of the MMSE was excellent (93% and 97%, respectively);
however, sensitivity was poor (24% and 30%, respect-
ively), and positive predictive values (67% and 76%,





Age, mean (SD) years 49 58 (16)
Male, n (%) 90 (50) 38 (62)
Education years, mean (SD) 13 (3) 12 (3)
Employed, n (%) 93 (51) NA
Charlson Comorbidity Index, mean (SD) 1.2 (1.7) NA
Psychiatric comorbidity, n (%) 76 (42) 45 (74)






11 (10) 6 (6)
ICU length of stay, mean (SD) days 14 (11) 10 (8)
Hospital length of stay, mean (SD) days 22 (15) 14 (8)
ICU, Intensive Care Unit; SD, standard deviation; n, number.
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81%, respectively) were fair to moderate (Table 2). The
area under the receiver operating characteristics curve
was 0.66 (95% CI: 0.58 to 0.74) at 6 months and 0.76
(95% CI: 0.67 to 0.85) at 12 months, indicating fair dis-
crimination (Figure 1).
For the ABC study data, overall agreement and kappa
scores were low (ranging from 38 to 42%, and 0.09 to
0.12, respectively) when assessing concordance between
screening positive for cognitive impairment on the
MMSE, and having cognitive impairment based on the
neuropsychological test scores. Specificity and positiveTable 2 Overall cognitive impairment at discharge, 3, 6 and 12
Sensitivity Specificity Positive predictive va
% (95% CI) % (95% CI) % (95% CI)
ALTOS Data
6 Months
MMSE <24 24 (14–35) 93 (87–97) 67 (45–84)
12 Months
MMSE <24 30 (17–46) 97 (92–99) 76 (50–93)
ABC Data
Discharge
MMSE <24 37 (26–49) 100 (59–100) 100 (87–100)
3 Months
MMSE <24 22 (12–34) 100 (79–100) 100 (75–100)
12 Months
MMSE <24 19 (8–35) 100 (78–100) 100 (59–100)
MMSE, mini-mental status examination; SD standard deviation.
Impairment on neuropsychological test battery = any battery test ≤2 SD or 2+ tests
For ALTOS study data: At 6 months: N = 181; True positives = 9%; False positives = 4
positives = 7%; False positives = 2%; True negatives = 73%; False negatives = 17%.
For ABC study data: At discharge: N = 78; True positives = 33%; False positives = 0%;
positives =17%; False positives = 0%; True negatives = 21%; False negatives = 62%. A
negatives = 29%; False negatives = 58%.predictive value of the MMSE was excellent, at 100% for
all three time points. Sensitivity was poor, ranging from
19 to 37%. Negative predictive values were also poor at
all three time points: 13% at discharge, 25% at 3 months
and 33% at 12 months (Table 2).
Comparing specific cognitive domains
Correlations between cognitive domains in the MMSE
compared to neuropsychological domains were weak to
moderate (6 months: 0.11 to 0.28, Table 3; 12 months:
0.09 to 0.34, Table 4), with the highest correlations ob-
served for attention at 6 months (r = 0.28) and language
at 12 months (r = 0.34). There was no consistent influ-
ence of patient characteristics (gender, age, education
level, concurrent depression and anxiety status, or pre-
existing psychiatric comorbidity) on the correlations in
any cognitive domain. The majority of correlations in
the subgroup analyses were ≤0.30.
Compared to the ALTOS study, the ABC study data
had slightly stronger correlations for attention at all time
periods (<0.5 versus <0.3). However, in both the ALTOS
and ABC studies, there was no consistent influence of
gender and age on correlations between MMSE and
neuropsychological attention scores (Table 5).
Discussion
In cross-sectional analyses of two prospective longitu-
dinal studies of acute respiratory failure survivors, we
found that the MMSE had fair to moderate agreement,
both for overall cognitive impairment and for specificmonths for MMSE versus neuropsychological test battery
lue Negative predictive value Kappa (SD) Overall
agreement (%)
% (95% CI)
67 (59–74) 0.19 (0.06) 67
81 (74–87) 0.34 (0.07) 80
13 (6–26) 0.09 (0.05) 42
25 (15–38) 0.10 (0.05) 38
33 (20–49) 0.12 (0.07) 42
≤ 1.5 SD.
%; True negatives = 58%; False negatives = 29%. At 12 months: N = 174; True
True negatives = 9%; False negatives = 58%. At 3 months: N = 76; True

























0 .25 .5 .75 1
1 − Specificity
Area under ROC curve = 0.6562
























0 .25 .5 .75 1
1 − Specificity
Area under ROC curve = 0.7591
B   ALTOS − 12 month data
Figure 1 Receiver operating characteristics curve for the detection of overall cognitive impairment using the MMSE versus a detailed
neuropsychological test battery. A. ALTOS study 6-month data and B. ALTOS study 12-month data. ALTOS, ARDS Network Long Term Outcomes
Study; MMSE, Mini-Mental State Examination.
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psychological tests. These findings were not influenced
by patient characteristics or timing of longitudinal follow-
up assessment. Indeed, even when accounting for gender,
age, education level, concurrent depression and anxiety
status, and pre-existing psychiatric comorbidity prior to
ICU admission, MMSE domain scores correlations were
weak to moderate with neuropsychological test scores.
The ability of the MMSE to discriminate overall cognitive
impairment was only fair based on the receiver operating
characteristics curve analysis; expressly, the MMSE had low
sensitivity. Even using a conservative cutoff score of <24,
the MMSE failed to identify a substantial portion of
survivors who had cognitive impairment identified on
neuropsychological tests, with poor to moderate negative
predictive values. Generally, a screening tool should have
an area under the ROC curve of at least >0.8 to demon-
strate excellent diagnostic accuracy [49], and the MMSE
failed to meet this threshold at both 6 and 12 months.
These results are similar to previous work in cardiac sur-
gery [50] and bariatric surgery [51] patients. Understandingthe limited extent of the MMSE’s agreement with neuro-
psychological test scores administered concurrently has im-
portant implications. Specifically, screening negative on the
MMSE for cognitive impairment does not rule out the
presence of cognitive impairment for acute respiratory
failure survivors at 3, 6 and 12 months.
There is great interest in screening for cognitive impair-
ment in ICU survivors given the frequent and long-lasting
cognitive impairments observed [52]. Our study provides
additional evidence that the MMSE may not be a valid
cognitive screening tool for use in this patient population.
Evaluation of other cognitive screening instruments (such
as the Montreal Cognitive Assessment) in this population
is needed to determine if they will better identify cognitive
impairments [53]. Recent work found the Montreal Cogni-
tive Assessment is more sensitive in accurately differentiat-
ing mild cognitive impairment from normal cognitive
function [54]. Another approach could include augmenting
the MMSE with more targeted instruments. For example,
adding a measure of executive function to the MMSE can
improve the detection of cognitive deficits [55].




All patients Gender Age Education Depression Anxiety Psychiatric
(Cutoff ≥8) (Cutoff ≥8) Co-morbidity
(N = 181–183) Male Female <50 ≥50 ≤HS >HS No Yes No Yes No Yes
(n = 90) (n = 90–92) (n = 82–84) (n = 99) (n = 92) (n = 88) (n = 115) (n = 65) (n = 107) (n = 74) (n = 90–91) (n = 88–89)
Orientation Orientation total 0.17a 0.28a −0.01 0.05 0.24a 0.16 −0.08 0.34a 0.05 0.10 0.23a 0.05 0.19
Registration DS total score 0.16a 0.15 0.16 0.11 0.20 0.25 0.10 0.23a 0.03 0.24a 0.08 0.11 0.20
DS forward 0.16a 0.23a 0.09 0.09 0.21a 0.31a 0.03 0.25a 0.00 0.34a 0.01 0.18 0.11
DS backward 0.13 0.02 0.21 0.11 0.13 0.13 0.12 0.19a 0.01 0.15 0.10 0.01 0.23
Attention DS total score 0.28a 0.42a 0.03 0.29a 0.26a 0.32a 0.08 0.26a 0.27a 0.24a 0.32a 0.26a 0.29a
DS forward 0.24a 0.33a 0.02 0.30a 0.18a 0.25a 0.07 0.23a 0.23 0.27a 0.20 0.26a 0.21
DS backward 0.26a 0.42a 0.00 0.23a 0.28a 0.32a 0.05 0.27a 0.22 0.14 0.36a 0.20 0.32a
Memory LM I 0.13 0.07 0.23* 0.12 0.15 0.15 0.06 0.08 0.19 0.21a 0.01 0.17 0.12
LM II 0.10 0.00 0.20 0.08 0.15 0.13 0.00 0.04 0.17 0.20a −0.08 0.14 0.09
Language COWA 0.16a 0.24a 0.08 0.04 0.22a 0.22a 0.10 0.10 0.16 0.10 0.21 0.15 0.18
















Gender Age Education Depression Anxiety Psychiatric
(Cutoff ≥8) (Cutoff ≥8) Co-morbidity
(N = 173–
174)
Male Female <50 ≥50 ≤HS >HS No Yes No Yes No Yes
(n = 83) (n = 90–91) (n = 78) (n = 95–96) (n = 88–89) (n = 83) (n = 117–118) (n = 57–56) (n = 106–107) (n = 67–68) (n = 87–88) (n = 85)
Orientation Orientation total 0.09 0.05 0.14 0.22 0.01 0.09 −0.01 0.13 −0.05 0.05 0.10 0.14 0.06
Registration DS total score 0.13 0.15 0.10 0.12 0.15 0.15 0.13 0.02 0.28a 0.03 0.28a 0.03 0.24a
DS forward 0.14 0.13 0.14 0.11 0.16 0.15 0.15 0.01 0.29a 0.01 0.29a −0.02 0.30a
DS backward 0.13 0.18 0.06 0.11 0.16 0.14 0.13 0.04 0.25 0.04 0.24 0.06 0.21
Attention DS total score 0.28a 0.34a 0.20 0.27a 0.28a 0.38a −0.01 0.08 0.43a 0.23a 0.37a 0.27a 0.29a
DS forward 0.26a 0.31a 0.16 0.33a 0.20 0.32a 0.02 0.09 0.37a 0.22a 0.31a 0.25a 0.27a
DS backward 0.28a 0.36a 0.20 0.20 0.33a 0.39a −0.10 0.11 0.42a 0.25a 0.33a 0.29a 0.28a
Memory LM I 0.16a 0.23a 0.11 0.17 0.16 0.11 0.07 0.19a 0.05 0.16 0.14 0.15 0.17
LM II 0.23a 0.30a 0.18 0.22 0.25a 0.18 0.13 0.25a 0.15 0.21a 0.23 0.20 0.26a
Language COWA 0.34a 0.37a 0.34a 0.45a 0.27a 0.34a 0.20 0.35a 0.25 0.44a 0.16 0.29a 0.43a










Table 5 Correlations of MMSE domain scores with corresponding neuropsychological test by demographic variables,
ABC study data
MMSE domain Corresponding neuropsychological test All patients Gender Age
Male Female <50 ≥50
At Discharge: (N = 61) (n = 38) (n = 23) (n = 17) (n = 44)
Attention Digit Span total score 0.47a 0.55a 0.39 0.49a 0.46a
Digit Span forward 0.29 0.32 0.31 0.32 0.28
Digit Span backward 0.45a 0.53a 0.34 0.63a 0.41a
3 Months: (n = 68–69) (n = 37) (n = 31–32) (n = 19) (n = 49–50)
Attention Digit Span total score 0.34a 0.38a 0.29 −0.30 0.42a
Digit Span forward 0.20 0.27 0.12 −0.16 0.22
Digit Span backward 0.39a 0.35a 0.45a −0.41 0.51a
12 Months: (n = 45–47) (n = 21–22) (n = 24–25) (n = 10) (n = 35–37)
Attention Digit Span total score 0.47a 0.48a 0.47a 0.62 0.45a
Digit Span forward 0.20 0.31 0.12 0.50 0.17
Digit Span backward 0.49a 0.57a 0.33 0.32 0.52a
MMSE, mini-mental status examination.
aP ≤0.05.
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of cognitive domains and does not evaluate learning,
delayed memory, processing speed and executive function,
among other cognitive domains. Many of these omitted
cognitive domains reflect the frontal-subcortical white
matter-mediated impairments known to occur in critical
illness, and commonly identified in ICU survivors
[4,14,27,31,56]. Hence, their omission in a short screening
test is problematic. As we learn more about the granular
and specific aspects of cognitive impairment in acute re-
spiratory failure survivors, better cognitive screening tools
tailored to this population could be developed.
Our study is among the first to test the validity of the
MMSE in acute respiratory failure survivors. Strengths
of our study include the ability to examine overall and
domain-specific performance of the MMSE compared to
a battery of neuropsychological tests administered con-
currently. The ALTOS study provided a relatively large
multicenter sample, which employed both a screening
and neuropsychological test battery, and data from two
time points. Inclusion of the ABC study allowed us to
test the generalizability of our findings in an independ-
ent cohort using similar neuropsychological tests. Our
study also has potential limitations. First, we were not
able to fully replicate all of the analyses from the ALTOS
data using the ABC study data due to the different
follow-up time points and neuropsychological tests used.
However, the available comparisons (overall cognitive
impairment and attention) demonstrated similar results
to the ALTOS study, helping increase confidence in
the generalizability of our findings, especially since the
studies used different neuropsychological tests. Further,
participants in the ABC study had a high baselinepsychiatric comorbidity, which is higher than the preva-
lence observed in other ICU cohorts [57,58]. However,
while the prevalence of baseline psychiatric comorbidities
was different between the two studies (42% for the ALTOS
study and 74% for the ABC study), the results of the ana-
lyses of the MMSE were similar. Second, despite the
relatively large sample size, secondary analyses con-
ducted using binary patient categories had smaller
sample sizes and may have reduced power to detect
true difference between subgroups. Third, the MMSE
and neuropsychological tests were administered using
different methods in the ALTOS study (phone versus
in-person), potentially contributing to the differences.
However, the MMSE is validated for telephone admin-
istration, minimizing this concern [34]. Moreover, in-
person administration was used for all testing in the
ABC study and demonstrated similar results to the
ALTOS study. Finally, the MMSE total score is vali-
dated to identify cognitive impairment; however, the
domain scores have not been validated as standalone
measures. Our assessment of the correlations between
the MMSE domains and the corresponding neuro-
psychological tests should be taken within context of
overall study findings, and not as a recommendation to
only administer specific domains of the MMSE.
Conclusions
Identifying valid, reliable and feasible screening tools is vital
for evaluating long-term cognitive impairments commonly
occurring in acute respiratory failure survivors. The MMSE,
one of the most commonly used cognitive screening tools,
demonstrated only fair agreement and poor sensitivity when
compared to concurrently administered neuropsychological
Pfoh et al. Critical Care  (2015) 19:220 Page 9 of 11test batteries in acute respiratory failure survivors during
their first year of recovery. Our findings do not support use
of the MMSE as a screening tool for cognitive impairment
in this patient population. Evaluation of alternative cognitive
screening tests, either alone or in combination with other
measures, is needed in acute respiratory failure survivors.
Key messages
 The Mini-Mental Status Examination (MMSE) is
widely used as a screening tool for cognitive
impairment in other patient populations, but its
ability to detect impairment in survivors of acute
respiratory failure is unclear.
 In survivors of acute respiratory failure, the MMSE
(compared to a detailed neuropsychological test
battery) demonstrated moderate agreement in
detecting overall cognitive impairment, with
excellent specificity but poor sensitivity.
 The area under the receiver operating characteristics
curve indicates the MMSE had only fair
discrimination in detecting cognitive impairment at
6 and 12 months.
 Our findings were not influenced by patient
characteristics (age, gender or education),
psychiatric disorders or timing of longitudinal
follow-up assessment.
 MMSE results in survivors of acute respiratory
failure should be interpreted with caution.
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